PDCD1 and acute myeloid leukemia: To further characterize the efficacy of PD-1 blockade in relapsed/refractory AML, a phase II trial was conducted on the efficacy of standard high dose chemotherapy Cytarabine followed by Pembrolizumab (ClinicalTrials.gov Identifier: NCT02768792).